Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively targets the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Preclinical research demonstrates that the ipamorelin research peptide stimulates pulsatile growth hormone release without causing secondary elevations in plasma cortisol, prolactin, or aldosterone, making it a pivotal subject in contemporary endocrine and metabolic research.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively targets the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Preclinical research demonstrates that the ipamorelin research peptide stimulates pulsatile growth hormone release without causing secondary elevations in plasma cortisol, prolactin, or aldosterone, making it a pivotal subject in contemporary endocrine and metabolic research.
Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) is a chemically synthesized pentapeptide classified within the growth hormone secretagogue (GHS) family. Unlike native ghrelin or early-generation peptide secretagogues, ipamorelin incorporates D-amino acid substitutions and an amino-isobutyric acid (Aib) residue at its N-terminus. These modification strategies confer structural rigidity and resistance against rapid enzymatic degradation by circulating endopeptidases in in vitro assays.
With a molecular formula of C38H49N9O5 and a monoisotopic mass of 711.38 Da, ipamorelin represents a minimal bioactive pharmacophore capable of high-affinity binding to the GHS-R1a receptor. Laboratory evaluations using growth hormone secretagogues consistently rely on ipamorelin due to its distinct structural stability relative to linear endogenously secreted peptides.
The primary mechanism of action for the ipamorelin research peptide involves high-affinity agonism at the growth hormone secretagogue receptor type 1a (GHS-R1a), a 7-transmembrane G-protein coupled receptor predominantly expressed in the anterior pituitary gland and hypothalamus. Binding of ipamorelin activates the phospholipase C (PLC) signaling cascade, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This intracellular pathway triggers the mobilization of intracellular calcium (Ca2+) ions, prompting exocytosis of stored growth hormone (GH) granules from somatotropic cells.
Crucially, in vitro electrophysiological and signaling studies demonstrate that ipamorelin exhibits unprecedented receptor selectivity. Unlike older compounds within the growth hormone-releasing peptide (GHRP) class, ipamorelin activation of GHS-R1a does not stimulate the adrenocorticotropic hormone (ACTH) pathway or promote prolactin release. This absence of off-target endocrine activation permits researchers to investigate isolated somatotroph dynamics without confounding glucocorticoid or lactotrophic interference.
In animal models, including rodent and canine bioassays, administration of ipamorelin elicited a dose-dependent, pulsatile release of somatotropin. Preclinical studies suggest that the kinetic profile of ipamorelin mimics physiological GH secretion patterns more closely than continuous GH infusion models. Longitudinal monitoring in rodent bioassays indicates that serum GH levels peak rapidly following administration before returning to baseline within normal physiological clearance windows.
Furthermore, preclinical research investigating tissue-specific anabolic markers reveals elevated hepatic insulin-like growth factor-1 (IGF-1) mRNA expression following sustained exposure to ipamorelin. Investigations utilizing animal models of skeletal muscle atrophy and bone density loss have observed positive nitrogen retention and accelerated osteoblast differentiation, highlighting the compound's broad utility in metabolic research.
When evaluating compounds within the growth hormone secretagogue domain, researchers frequently compare ipamorelin against first- and second-generation secretagogues such as GHRP-6 research peptide, GHRP-2 research peptide, and GHRH analogs like Sermorelin acetate. While GHRP-6 and GHRP-2 demonstrate potent GH-releasing capability, preclinical data show that both compounds trigger notable secondary spikes in plasma cortisol and prolactin. Additionally, GHRP-6 strongly stimulates appetite via central ghrelin pathways, an effect markedly absent in ipamorelin assays.
In contrast, GHRH agonists like Sermorelin operate via a distinct receptor system (the GHRH receptor) to stimulate GH synthesis and secretion upstream. Comparative in vitro assays demonstrate that while GHRH analogs depend heavily on endogenous somatostatin tone to dictate pulse magnitude, GHS-R1a agonists like ipamorelin act downstream to directly trigger granule exocytosis. As a result, many modern research protocols incorporate combined GHRH and GHS-R1a agonists to study synergistic signaling cross-talk.
A prominent area of investigation in neuroendocrine research involves dual-pathway secretagogue activation. Preclinical models frequently evaluate the co-administration of ipamorelin with growth hormone-releasing hormone (GHRH) analogs such as CJC-1295 without DAC or modified GRF (1-29). Because GHRH agonists and GHS-R1a agonists operate through non-competing signaling pathways—adenylyl cyclase/cAMP and phospholipase C/Ca2+, respectively—dual exposure results in a synergistic, rather than additive, GH release response.
In vitro somatotroph cultures exposed simultaneously to ipamorelin and a GHRH agonist exhibit magnified intracellular calcium oscillations and amplified GH exocytosis. This dual-stimulus design allows researchers to probe maximum somatotropic secretory capacity while maintaining strict control over baseline hormonal parameters in our comprehensive PX1 Research catalog.
To ensure experimental reproducibility and maintain peptide integrity, meticulous laboratory handling protocols must be observed when preparing lyophilized ipamorelin. The compound is supplied as a sterile, lyophilized cake that requires reconstitution with an appropriate laboratory solvent prior to in vitro or preclinical administration.
Standard laboratory reconstitution procedures involve adding bacteriostatic water (0.9% benzyl alcohol preserved) or sterile 0.9% sodium chloride solution to the vial. The liquid reagent should be directed down the glass wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirl mixing should be performed; mechanical agitation or vigorous shaking must be avoided to prevent protein denaturing or aggregate formation. All preparation steps must occur within a certified laminar flow hood operating under strict aseptic conditions.
Lyophilized ipamorelin exhibits robust shelf stability when stored under proper thermal and environmental conditions. Prior to reconstitution, unopened vials should be maintained at -20°C to -80°C in a desiccated environment protected from direct light exposure. Under these conditions, the peptide retains structural stability for extended periods without significant degradation.
Following reconstitution, liquid aliquots should be stored at 2°C to 8°C for short-term evaluation (up to 30 days) or sub-aliquoted into single-use microcentrifuge tubes and frozen at -80°C to prevent degradation from repeated freeze-thaw cycles. Exposure to elevated temperatures, ambient room light, or basic pH environments will accelerate hydrolysis of the peptide backbone and lead to loss of binding affinity at the GHS-R1a receptor.
Given the precise demands of quantitative endocrine research, procuring high-purity research peptides supported by verified analytical data is essential. Substandard reagents containing residual organic solvents, TFA salts, or truncated peptide sequences introduce unquantified variables that compromise assay validity.
Rigorous research standards mandate that every batch of ipamorelin undergo dual analytical testing: High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity (requiring ≥99.0% main peak area) and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular weight identity. Furthermore, quantifying bacterial endotoxin levels via Limulus Amebocyte Lysate (LAL) assays (<0.01 EU/mg limit) ensures that in vitro cell viability and in vivo systemic responses remain unaffected by pyrogenic contaminants.
PX1 Research operates as a primary domestic supplier of analytical-grade compounds for institutional laboratories and qualified academic researchers. All compounds in our inventory are USA-manufactured in state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards. Every production lot undergoes independent verification by an ISO 17025 accredited testing laboratory.
Researchers sourcing through a dedicated bulk laboratory account receive full access to lot-specific Certificates of Analysis (COAs), complete with raw HPLC chromatograms and mass spectra. Orders ship directly from our climate-controlled distribution centers in California and Arizona with same-day dispatch (Monday through Friday), ensuring reagent chain-of-custody and temperature integrity from synthesis to your laboratory bench.
What is the specific target receptor for the ipamorelin research peptide?
Ipamorelin is a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein coupled receptor expressed in the anterior pituitary gland and hypothalamus.
How does ipamorelin differ from GHRP-6 and GHRP-2 in laboratory models?
Unlike GHRP-6 and GHRP-2, ipamorelin does not stimulate secondary spikes in cortisol, prolactin, or aldosterone, nor does it significantly induce appetite signals in preclinical models.
What purity levels are confirmed on PX1 Research Certificates of Analysis?
Every lot of ipamorelin from PX1 Research is verified via RP-HPLC and ESI-MS to meet or exceed 99.0% chemical purity, with documented endotoxin levels below 0.01 EU/mg.
What solvents are recommended for reconstituting ipamorelin in vitro?
Reconstitution is typically performed using sterile 0.9% sodium chloride or bacteriostatic water containing 0.9% benzyl alcohol under sterile laboratory conditions.
How should reconstituted ipamorelin solutions be stored?
Reconstituted liquid solutions should be kept refrigerated at 2°C to 8°C for short-term use, or sub-aliquoted and frozen at -80°C for long-term storage to prevent degradation.
Why is ipamorelin frequently paired with CJC-1295 in secretagogue studies?
Ipamorelin activates the GHS-R1a receptor while CJC-1295 acts on the GHRH receptor. Co-administration engages complementary intracellular signaling pathways (PLC/Ca2+ and cAMP), yielding synergistic GH release in preclinical models.
What analytical methods are used to verify ipamorelin identity and mass?
Structural identity and monoisotopic mass (711.38 Da) are confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS), while purity profile is mapped via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC).
Are PX1 Research compounds approved for human consumption?
No. All products sold by PX1 Research are strictly for in vitro laboratory evaluation and preclinical research use only. They are not for human or veterinary medical applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.